Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Revenue of Prime Medicine, Inc. (PRME)
Revenue in 2023 (TTM): $
According to Prime Medicine, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Prime Medicine, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $ | $-186,639,000 | $-198,412,000 | $-198,133,000 |
| 2022 | $ | $ | $-108,416,000 | $-122,769,000 | $-121,821,000 |
| 2021 | $ | $ | $-83,515,000 | $-165,853,000 | $-165,367,000 |
| 2020 | $5.21 M | $ | $-11,756,000 | $-1,543,000 | $-3,410,000 |
| 2019 | $ | $-2,760,000 | $-2,172,000 | $-2,525,000 | $-2,529,000 |